Skip to content

Can nocebo effects on itch be modified by a positive expectation induction?

Can nocebo effects on itch be modified by a positive expectation induction? - Can nocebo effects on itch be modified?

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON40445
Enrollment
99
Registered
2014-02-26
Start date
2014-09-10
Completion date
Unknown
Last updated
2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Itch pruritus

Interventions

None listed

Sponsors

Universiteit Leiden
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Healthy human volunteers, 18 - 35 year old, fluent in Dutch language

Exclusion criteria

Exclusion criteria: Severe morbidity (e.g., multiple sclerosis, diabetes mellitus, heart or lung diseases), psychiatric disorders (e.g., depression), use of pacemaker, color-blindness, diagnose of histamine hypersensitivity, and chronic itch or pain complaints.

Design outcomes

Primary

MeasureTime frame
The main study endpoint is the difference in the levels of itch (VAS scores) evoked by the electrical stimuli associated with the conditioned cues versus the neutral cues in the testing phase of part II of the experiment. It is investigated whether nocebo effects (negative expectation effects) can be modified by a positive expectation induction by conditioning and verbal suggestion (low-itch expectation induction) (group 1), resulting in lower itch VAS scores than a repeated negative expectation induction (high-itch expectation induction) (group 2), or a neutral procedure (neutral expectation induction) (group 3).

Secondary

MeasureTime frame
The secondary study endpoints of the present experiment are: a) the itch related expectancy effects on scratching behavior; b) the itch related expectancy effects regarding itch evoked by histamine iontophoresis; c) the role of individual characteristics (e.g., optimism) on (the modifiability) of expectancy effects; and d) the role of 5-HTTLPR genotype and other genetic variants on (the modifiability) of expectancy effects.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)